Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,704.00+4.80%ETH$2,426.56+7.03%GOLD$4,092.80+0.49%OIL$88.04-0.09%
Smart Investors Daily
SID Premium
MX

NASDAQ · MXCT

MaxCyte, Inc.

Healthcare · Medical - Devices

$1.46

Down-$0.07 (-4.79%)

Updated Nov 5, 2026, 12:19 AM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
170.68M
P/E ratio
-3.73
Dividend yield
0.00%
52-week range
$0.64 – $1.81
Volume
1.03M
Avg. volume
961.6K

Price performance · MXCT

MXCT price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

MXCT closed at $1.46 after 20 trading sessions, up 40.38% for the selected period.

Last close
$1.46
Period change
+40.38%
Period low
$0.96
Period high
$1.73
Daily close
View OHLC price history
MXCT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$1.51$1.51$1.365$1.461.03M
Nov 2, 2026$1.59$1.705$1.43$1.451.28M
Oct 30, 2026$1.71$1.72$1.505$1.59963.82K
Oct 29, 2026$1.73$1.76$1.6229$1.731.14M
Oct 28, 2026$1.50$1.73$1.50$1.711.71M
Oct 27, 2026$1.51$1.64$1.51$1.541.58M
Oct 26, 2026$1.39$1.53$1.3649$1.511.13M
Oct 23, 2026$1.43$1.43$1.35$1.40757.46K
Oct 22, 2026$1.44$1.51$1.43$1.431.02M
Oct 21, 2026$1.42$1.53$1.405$1.471.42M
Oct 20, 2026$1.29$1.4567$1.29$1.431.39M
Oct 19, 2026$1.30$1.31$1.27$1.30986.46K
Oct 16, 2026$1.32$1.32$1.28$1.301.01M
Oct 15, 2026$1.27$1.31$1.255$1.303.79M
Oct 14, 2026$1.225$1.33$1.195$1.2512.67M
Oct 13, 2026$0.9813$1.01$0.9361$0.9643327.91K
Oct 12, 2026$1.01$1.01$0.9722$0.995150.12K
Oct 9, 2026$1.02$1.03$0.99$1.01240.01K
Oct 8, 2026$1.04$1.04$0.9636$1.02476.76K
Oct 7, 2026$1.07$1.08$1.04$1.04311.95K

Latest MXCT news

The latest Smart Investors Daily articles mentioning MXCT.

Stock researchCompany · Overview

MXCT research

Overview

Company profile and research snapshot.

Company profile

MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$6.00
Implied upside
—
Analysts
—
MXCT recent ratings
DateFirmRatingTarget
Mar 25, 2026Craig-HallumBuy—
Aug 11, 2025BTIGNeutral—
Aug 7, 2025William BlairMarket Perform—
Mar 12, 2025StifelBuy—
Apr 23, 2024Stephens & Co.Overweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 28, 2026

MaxCyte to Participate in Three Upcoming Investor Conferences

ROCKVILLE, Md., Oct. 28, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics, today announced Company management will participate in three upcoming investor conferences. Stifel 2026 Healthcare ConferenceFireside Chat on Wednesday, November 11th at 4:40 PM ET17th Annual Craig-Hallum Alpha Select ConferenceTuesday, November

Yahoo · Oct 14, 2026

MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance

MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026ROCKVILLE, Md., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced preliminary revenue for the third quarter ended September 30, 2026 and raised its 2026 revenue guidance. Preliminary Third Quarter Revenue Core

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By